Vir Biotechnology, Inc. (VIR) Income Statement
VIR 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsVIR revenue and net income
Where VIR's revenue goes
2025Each bar shows an amount and its share of revenue. VIR kept −638.9% of revenue as net income.
VIR profit margins
VIR growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −7.6% | −65.1% | −2.1% | — |
| Gross profit | −3.3% | −66.1% | −5.7% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
VIR quarterly EPS vs estimates
Vir Biotechnology beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.80).
VIR income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $68.6M | $74.2M | $86.2M | $1.62B | $1.10B | $76.4M | $711,000 | $10.7M | $2.7M |
| Cost of revenue | $11.7M | $15.4M | $22.2M | $161.8M | $71.7M | $301.6M | $143.1M | $100.2M | $62.5M |
| Gross profit | $56.9M | $58.8M | $64.0M | $1.45B | $1.02B | $76.4M | $711,000 | −$99.4M | −$62.4M |
| Research & development | $432.8M | $463.2M | $550.9M | $467.9M | $442.2M | $302.4M | $148.5M | $97.5M | $62.1M |
| Sales, general & admin | $92.1M | $119.0M | $173.7M | $161.8M | $160.8M | $70.9M | $37.6M | $29.1M | $21.7M |
| Total operating expenses | $524.9M | $582.2M | $725.0M | $620.9M | $603.0M | $373.3M | $178.7M | $126.6M | $83.1M |
| Operating income | −$468.0M | −$523.4M | −$661.0M | $833.1M | $420.8M | −$297.0M | −$178.0M | −$118.7M | −$80.8M |
| Interest income | $40.2M | $71.8M | $82.4M | $28.1M | $439,000 | $2.8M | $8.5M | $2.5M | $638,000 |
| Interest expense | — | — | — | $183.1M | $272.9M | $3.8M | $8.0M | $0 | $0 |
| Income before taxes | −$437.8M | −$523.1M | −$628.2M | $754.3M | $549.8M | −$298.6M | −$174.5M | −$116.4M | −$80.8M |
| Income taxes | $217,000 | −$1.1M | −$13.1M | $238.4M | $21.2M | −$54,000 | $154,000 | −$480,000 | −$10.9M |
| Net income | −$438.0M | −$522.0M | −$615.1M | $515.8M | $528.6M | −$298.7M | −$174.7M | −$115.9M | −$69.9M |
| EBITDA | −$456.3M | −$508.9M | −$641.6M | $848.6M | $432.7M | $514.3M | −$173.5M | −$115.9M | −$80.4M |
| EPS (diluted) | −$3.16 | −$3.82 | −$4.59 | $3.81 | $3.88 | −$2.48 | −$5.80 | −$1.20 | −$34.93 |
| Gross margin | 82.9% | 79.2% | 74.2% | 90.0% | 93.5% | 100.0% | 100.0% | −931.4% | −2,302.9% |
| Operating margin | −682.7% | −705.4% | −767.0% | 51.6% | 38.4% | −388.9% | −25,032.2% | −1,112.6% | −2,983.6% |
| Net margin | −638.9% | −703.4% | −713.7% | 31.9% | 48.3% | −391.1% | −24,568.6% | −1,086.3% | −2,579.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $238.9M | $0 | $64.1M | $240,000 | $1.2M | $3.0M | $12.4M | $2.4M | $3.1M | $56.4M | $16.8M | $2.6M |
| Cost of revenue | $2.8M | $2.8M | $2.9M | $3.0M | $2.9M | $2.9M | $3.6M | $2.9M | $4.3M | $4.6M | $5.3M | $6.4M |
| Gross profit | $236.1M | −$2.8M | $61.1M | −$2.7M | −$1.7M | $165,000 | $8.8M | −$566,000 | −$1.2M | $51.8M | $11.5M | −$3.8M |
| Research & development | $131.4M | $107.0M | $85.5M | $147.9M | $84.6M | $114.7M | $81.7M | $189.7M | $97.9M | $94.0M | $89.5M | $143.7M |
| Sales, general & admin | $30.2M | $23.3M | $23.6M | $22.2M | $22.3M | $23.9M | $26.7M | $25.7M | $30.3M | $36.3M | $43.1M | $41.1M |
| Total operating expenses | $161.5M | $130.3M | $109.1M | $170.1M | $106.9M | $138.7M | $108.4M | $215.5M | $128.1M | $130.2M | $128.6M | $182.9M |
| Operating income | $74.6M | −$133.2M | −$48.0M | −$172.9M | −$108.6M | −$138.5M | −$99.6M | −$216.0M | −$129.4M | −$78.4M | −$117.1M | −$186.7M |
| Interest income | $9.0M | $7.2M | $7.8M | $9.4M | $10.8M | $12.3M | $14.2M | $17.5M | $18.8M | $21.3M | $20.7M | $21.9M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $239,000 | — |
| Income before taxes | $80.3M | −$125.5M | −$43.1M | −$163.0M | −$110.8M | −$120.9M | −$104.7M | −$213.5M | −$139.9M | −$65.0M | −$120.8M | −$166.6M |
| Income taxes | $179,000 | $170,000 | −$137,000 | $168,000 | $170,000 | $16,000 | −$86,000 | $177,000 | −$1.5M | $276,000 | −$4.8M | −$3.2M |
| Net income | $80.1M | −$125.7M | −$42.9M | −$163.1M | −$111.0M | −$121.0M | −$104.6M | −$213.7M | −$138.4M | −$65.3M | −$116.0M | −$163.4M |
| EBITDA | $77.4M | −$130.4M | −$45.1M | −$169.9M | −$105.7M | −$135.7M | −$96.7M | −$213.1M | −$125.1M | −$73.9M | −$112.6M | −$180.3M |
| EPS (diluted) | $0.47 | −$0.85 | −$0.31 | −$1.17 | −$0.80 | −$0.88 | −$0.76 | −$1.56 | −$1.02 | −$0.48 | −$0.86 | −$1.22 |
| Gross margin | 98.8% | — | 95.4% | −1,144.6% | −141.2% | 5.4% | 71.1% | −23.8% | −40.2% | 91.9% | 68.6% | −144.1% |
| Operating margin | 31.2% | — | −74.9% | −72,034.6% | −8,946.4% | −4,568.8% | −804.5% | −9,076.6% | −4,207.0% | −139.1% | −697.7% | −7,075.9% |
| Net margin | 33.5% | — | −67.0% | −67,975.4% | −9,139.9% | −3,989.6% | −845.2% | −8,979.7% | −4,500.1% | −115.8% | −690.9% | −6,192.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in VIR's financial statements (latest annual report filed February 23, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
VIR financial results
In fiscal year 2025 (ended December 31, 2025), Vir Biotechnology reported revenue of $68.6 million, down 7.6% from the year before. It had a net loss of $438.0 million, a net profit margin of −638.9%. Diluted earnings per share came to −$3.16. Over five years revenue grew at an average rate of −2.1% a year.
See the VIR stock overview for the latest quote and news, or the VIR chart for price history and technical indicators.
VIR income statement FAQ
What is Vir Biotechnology's annual revenue?
Vir Biotechnology reported total revenue of $68.6 million for fiscal year 2025, which ended on December 31, 2025. That was down 7.6% from $74.2 million the previous year.
Is Vir Biotechnology profitable?
No. Vir Biotechnology reported a net loss of $438.0 million in fiscal 2025, a net profit margin of −638.9%; its operating margin was −682.7%.
What is Vir Biotechnology's gross margin?
Vir Biotechnology's gross margin was 82.9% in fiscal 2025: for every $100 of revenue, Vir Biotechnology kept $83 after the direct cost of its products and services.
How much does Vir Biotechnology spend on research and development?
Vir Biotechnology spent $432.8 million on research and development in fiscal 2025, 631.3% of revenue.
How fast is Vir Biotechnology growing?
Revenue grew −2.1% a year on average over the last five fiscal years, from $76.4 million to $68.6 million.
What are Vir Biotechnology's earnings per share?
Vir Biotechnology earned $-3.16 per diluted share in fiscal 2025, compared with $-3.82 a year earlier.
When will Vir Biotechnology report its next earnings?
Vir Biotechnology is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.
When does Vir Biotechnology's fiscal year end?
Vir Biotechnology's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 23, 2026.